Welcome to our dedicated page for Cymabay Therapeu news (Ticker: CBAY), a resource for investors and traders seeking the latest updates and insights on Cymabay Therapeu stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cymabay Therapeu's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cymabay Therapeu's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
CymaBay Therapeutics (NASDAQ: CBAY) has announced the publication of results from the ENHANCE phase 3 study of seladelpar, aimed at treating primary biliary cholangitis (PBC). The study demonstrated significant efficacy, with 78.2% of patients on 10 mg of seladelpar achieving the primary endpoint compared to 12.5% on placebo. Key secondary endpoints also showed promising results, including improvements in alkaline phosphatase levels and patient-reported pruritus. There were no adverse endpoints reported. Looking ahead, seladelpar is undergoing further evaluation in the RESPONSE phase 3 registration study, with results expected in Q3 2023, and the ASSURE long-term study to provide additional safety and efficacy data.